Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients
- Conditions
- Anemia
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT00344409
- Locations
- 🇯🇵
Shikoku region, Ehime, Japan
🇯🇵Kyusyu region, Fukuoka, Kagoshima, Japan
🇯🇵Chugoku region, Hiroshima, Tottori, Japan
Darbepoetin Administration to Preterm Infants
- Conditions
- Infant, Newborn
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 102
- Registration Number
- NCT00334737
- Locations
- 🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸University of Colorado, Denver, Colorado, United States
🇺🇸McKay-Dee Hospital, Ogden, Utah, United States
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT00327535
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
- Conditions
- Sarcoma
- Interventions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00283621
- Locations
- 🇺🇸
UT MDAnderson Cancer Center, Houston, Texas, United States
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 492
- Registration Number
- NCT00264108
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT00261313
Study of Aranesp to Treat Anemia in Prostate Cancer Patients.
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT00245895
- Locations
- 🇺🇸
Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT00239239
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Behavioral: Darbepoetin and Filgrastim
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- St. Bartholomew's Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT00234143
- Locations
- 🇬🇧
St Bartholomew's Hospital, London, United Kingdom
A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
- Conditions
- Blood CancerMyelodysplastic SyndromesMyelodysplastic Syndromes (MDS)
- Interventions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Peter L Greenberg
- Target Recruit Count
- 21
- Registration Number
- NCT00230321
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.